Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/5147
Title: | Efficacy and safety of rimexolone 1% versus prednisolone acetate 1% in the control of postoperative inflammation following phacoemulsification cataract surgery | Authors: | Yaylalı, Volkan Özbay, D. Tatlipinar, S. Yildirim, C. Özden, S. |
Keywords: | Cataract surgery Phacoemulsification Postoperative inflammation Prednisolone acetate Rimexolone prednisolone acetate rimexolone adult aged anterior eye chamber article chi square test clinical article clinical trial conjunctival hyperemia controlled clinical trial controlled study double blind procedure drug efficacy drug formulation drug safety eye inflammation female human intraocular pressure lens implantation male ocular pruritus phacoemulsification posterior eye chamber postoperative period prospective study randomized controlled trial Student t test Double-Blind Method Female Glucocorticoids Humans Inflammation Lens Implantation, Intraocular Male Middle Aged Ophthalmic Solutions Postoperative Complications Prednisolone Pregnadienes Prospective Studies Safety Uveitis, Anterior |
Abstract: | Purpose: The aim of this study was to evaluate the efficacy and safety of rimexolone 1% ophthalmic suspension compared to that of 1% prednisolone acetate in the control of inflammation in eyes undergoing cataract extraction with phacoemulsification followed by posterior chamber intraocular lens implantation. Methods: Forty-eight patients who underwent uncomplicated cataract extraction with phacoemulsification followed by posterior chamber IOL implantation constituted the study group of this prospective, randomized, double-masked investigation. Patients were randomly assigned to two treatment groups; rimexolone 1% ophthalmic suspension (27 subjects) or prednisolone acetate 1% (21 subjects). Postoperatively, patients used topical rimexolone or prednisolone drops four times a day for 15 days. Patients were examined at the first postoperative day (day 1), and days 3, 7 and 15. The major efficacy parameters assessed clinically on each visit were anterior chamber cells, anterior chamber flare and conjunctival hyperemia. Safety of the rimexolone was evaluated by IOP values and the presence of adverse effects. Results: Regarding all three efficacy parameters, rimexolone was found to be clinically and statistically equivalent to prednisolone acetate. Intraocular pressure values during the postoperative period were also similar in both groups. Conclusion: Rimexolone 1% ophthalmic suspension is both an effective and safe topical steroid in controlling postoperative inflammation after cataract extraction with phacoemulsification. © 2004 Kluwer Academic Publishers. | URI: | https://hdl.handle.net/11499/5147 https://doi.org/10.1023/B:INTE.0000018551.80409.0a |
ISSN: | 0165-5701 |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu |
Show full item record
CORE Recommender
SCOPUSTM
Citations
11
checked on Aug 17, 2024
Page view(s)
50
checked on Aug 24, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.